KR101848122B1 - 환자 부분모집단에서의 통풍 치료 방법 - Google Patents

환자 부분모집단에서의 통풍 치료 방법 Download PDF

Info

Publication number
KR101848122B1
KR101848122B1 KR1020147015209A KR20147015209A KR101848122B1 KR 101848122 B1 KR101848122 B1 KR 101848122B1 KR 1020147015209 A KR1020147015209 A KR 1020147015209A KR 20147015209 A KR20147015209 A KR 20147015209A KR 101848122 B1 KR101848122 B1 KR 101848122B1
Authority
KR
South Korea
Prior art keywords
subject
uric acid
gout
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147015209A
Other languages
English (en)
Korean (ko)
Other versions
KR20140123927A (ko
Inventor
고팔 찬드라 사하
브라이언 케이 로버츠
브라이언 에드워드 레이번
찰스 에이 맥위어터
Original Assignee
사이머베이 쎄라퓨틱스, 인코퍼레이티드
다이아텍스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이머베이 쎄라퓨틱스, 인코퍼레이티드, 다이아텍스, 인코포레이티드 filed Critical 사이머베이 쎄라퓨틱스, 인코퍼레이티드
Publication of KR20140123927A publication Critical patent/KR20140123927A/ko
Application granted granted Critical
Publication of KR101848122B1 publication Critical patent/KR101848122B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147015209A 2011-11-04 2011-11-04 환자 부분모집단에서의 통풍 치료 방법 Expired - Fee Related KR101848122B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
KR20140123927A KR20140123927A (ko) 2014-10-23
KR101848122B1 true KR101848122B1 (ko) 2018-04-11

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147015209A Expired - Fee Related KR101848122B1 (ko) 2011-11-04 2011-11-04 환자 부분모집단에서의 통풍 치료 방법

Country Status (14)

Country Link
EP (1) EP2775835A4 (enrdf_load_stackoverflow)
JP (1) JP6047172B2 (enrdf_load_stackoverflow)
KR (1) KR101848122B1 (enrdf_load_stackoverflow)
CN (1) CN104066323A (enrdf_load_stackoverflow)
AU (1) AU2011380509B2 (enrdf_load_stackoverflow)
BR (1) BR112014010693A2 (enrdf_load_stackoverflow)
CA (1) CA2859689C (enrdf_load_stackoverflow)
CL (1) CL2014001156A1 (enrdf_load_stackoverflow)
IL (1) IL232385A (enrdf_load_stackoverflow)
MX (1) MX354846B (enrdf_load_stackoverflow)
NZ (1) NZ624714A (enrdf_load_stackoverflow)
SG (1) SG11201402027PA (enrdf_load_stackoverflow)
WO (1) WO2013066352A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403574B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
CN105851522A (zh) * 2014-07-25 2016-08-17 许伟琦 一种防止尿路结石的饲料
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501383A (ja) 1999-06-04 2003-01-14 メタボレックス， インコーポレイテッド インスリン抵抗性、２型糖尿病、高脂血症および高尿酸血症の処置のための、（−）（３−トリハロメチルフェノキシ）（４−ハロフェニル）酢酸誘導体の使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
CN102643241B (zh) * 2007-11-27 2015-01-21 亚德生化公司 化合物和组合物以及使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501383A (ja) 1999-06-04 2003-01-14 メタボレックス， インコーポレイテッド インスリン抵抗性、２型糖尿病、高脂血症および高尿酸血症の処置のための、（−）（３−トリハロメチルフェノキシ）（４−ハロフェニル）酢酸誘導体の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer, PR Newswire(2011.10.20.)
Metabolex Initiates Phase 2 Trial of Arhalofenate, PR Newswire(2011.05.19.)

Also Published As

Publication number Publication date
CL2014001156A1 (es) 2015-01-16
KR20140123927A (ko) 2014-10-23
IL232385A0 (en) 2014-06-30
MX2014005399A (es) 2015-04-08
CA2859689A1 (en) 2013-05-10
NZ624714A (en) 2016-01-29
WO2013066352A1 (en) 2013-05-10
EP2775835A4 (en) 2015-07-29
JP2014532759A (ja) 2014-12-08
MX354846B (es) 2018-03-22
BR112014010693A2 (pt) 2020-11-10
SG11201402027PA (en) 2014-09-26
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
CA2859689C (en) 2018-05-22
JP6047172B2 (ja) 2016-12-21
AU2011380509B2 (en) 2016-05-19
ZA201403574B (en) 2015-11-25
AU2011380509A1 (en) 2014-05-29
IL232385A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
KR101848121B1 (ko) 통풍 발열의 치료법
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
KR101848122B1 (ko) 환자 부분모집단에서의 통풍 치료 방법
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210406

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210406

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000